688062 迈威生物
已收盘 08-23 15:00:00
资讯
新帖
简况
迈威生物(688062)8月23日主力资金净卖出551.21万元
证券之星 · 08-24 08:21
迈威生物(688062)8月23日主力资金净卖出551.21万元
迈威生物最新公告:9MW2821治疗宫颈癌的Ⅲ期临床研究获得CDE同意
证券之星 · 08-22 21:20
迈威生物最新公告:9MW2821治疗宫颈癌的Ⅲ期临床研究获得CDE同意
迈威生物(688062.SH):9MW2821治疗宫颈癌的Ⅲ期临床研究获得CDE同意
智通财经网 · 08-22 17:57
迈威生物(688062.SH):9MW2821治疗宫颈癌的Ⅲ期临床研究获得CDE同意
【迈威生物:9MW2821治疗宫颈癌III期临床研究获CDE同意】金十数据8月22日讯,迈威生物公告,公司自主研发的创新药9MW2821获得国家药品监督管理局药品审评中心同意,针对含铂化疗失败的复发或转移性宫颈癌进行III期临床研究。
美港电讯 · 08-22 17:21
【迈威生物:9MW2821治疗宫颈癌III期临床研究获CDE同意】金十数据8月22日讯,迈威生物公告,公司自主研发的创新药9MW2821获得国家药品监督管理局药品审评中心同意,针对含铂化疗失败的复发或转移性宫颈癌进行III期临床研究。
迈威生物急需一位"天使"
新浪财经 · 08-21
迈威生物急需一位"天使"
迈威生物-U大跌5.04% 创6月新低
智选洞察 · 08-20
迈威生物-U大跌5.04% 创6月新低
迈威生物-U08月19日主力资金流出21万元 连续3日减仓
自选股智能写手 · 08-19
迈威生物-U08月19日主力资金流出21万元 连续3日减仓
迈威生物新提交1件商标注册申请
证券之星 · 08-18
迈威生物新提交1件商标注册申请
迈威生物最新公告:9MW2821用于尿路上皮癌适应症纳入突破性治疗品种
证券之星 · 08-11
迈威生物最新公告:9MW2821用于尿路上皮癌适应症纳入突破性治疗品种
迈威生物(688062.SH):9MW2821用于尿路上皮癌适应症纳入突破性治疗品种
智通财经 · 08-11
迈威生物(688062.SH):9MW2821用于尿路上皮癌适应症纳入突破性治疗品种
迈威生物-U08月07日主力资金流入10万元 连续5日加仓
自选股智能写手 · 08-07
迈威生物-U08月07日主力资金流入10万元 连续5日加仓
迈威生物-U08月05日主力资金流入185万元 连续3日加仓
自选股智能写手 · 08-05
迈威生物-U08月05日主力资金流入185万元 连续3日加仓
迈威生物-U大幅上涨 上海生物医药产业快速发展
智选洞察 · 08-05
迈威生物-U大幅上涨 上海生物医药产业快速发展
迈威生物-U大幅上涨 创新药政策利好
智选洞察 · 08-02
迈威生物-U大幅上涨 创新药政策利好
【迈威生物(688062.SH)子公司与润佳医药签订许可协议 为骨关节炎治疗领域注入新产品】智通财经APP讯,迈威生物(688062.
智通财经 · 08-01
【迈威生物(688062.SH)子公司与润佳医药签订许可协议 为骨关节炎治疗领域注入新产品】智通财经APP讯,迈威生物(688062.
迈威生物(688062.SH)子公司与润佳医药签订许可协议 为骨关节炎治疗领域注入新产品
智通财经网 · 08-01
迈威生物(688062.SH)子公司与润佳医药签订许可协议 为骨关节炎治疗领域注入新产品
迈威生物(688062.SH):全资子公司与润佳医药签订许可协议
格隆汇资讯 · 08-01
迈威生物(688062.SH):全资子公司与润佳医药签订许可协议
迈威生物:全资子公司与润佳医药签订许可协议迈威生物公告,全资子公司泰康生物与润佳医药签订许可协议,润佳医药许可泰康生物在大中华区域研究、开发、注册、商业化及销售RP901项目及伴随诊断。
格隆汇 · 08-01
迈威生物:全资子公司与润佳医药签订许可协议迈威生物公告,全资子公司泰康生物与润佳医药签订许可协议,润佳医药许可泰康生物在大中华区域研究、开发、注册、商业化及销售RP901项目及伴随诊断。
迈威生物-U大跌5.01% 北向资金连续6日增持
智选洞察 · 08-01
迈威生物-U大跌5.01% 北向资金连续6日增持
迈威生物-U大幅上涨 生物医药产业获政策利好
智选洞察 · 07-31
迈威生物-U大幅上涨 生物医药产业获政策利好
暂无数据
公司概况
公司名称:
迈威(上海)生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2022-01-18
主营业务:
迈威(上海)生物科技股份有限公司是一家创新型生物制药企业,主营业务为治疗用生物制品的研发、生产与销售,主要产品为抗体药物。截至本招股说明书签署日,新增授权专利4项,新增专利申请48项,独立承担1项国家“重大新药创制”重大科技专项,独立承担2项国家重点研发计划。
发行价格:
34.80
{"stockData":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物","latestPrice":21.36,"timestamp":1724396400000,"preClose":22.01,"halted":0,"volume":2393914,"delay":0,"floatShares":204000000,"shares":400000000,"eps":-2.5476,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.65,"latestTime":"08-23 15:00:00","open":22.2,"high":22.35,"low":21.02,"amount":51101000,"amplitude":0.0604,"askPrice":21.36,"askSize":161,"bidPrice":21.34,"bidSize":30,"shortable":0,"etf":0,"ttmEps":-2.5476,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"adjPreClose":22.01,"symbolType":"stock_kcb","openAndCloseTimeList":[[1724376600000,1724383800000],[1724389200000,1724396400000]],"highLimit":24.21,"lowLimit":19.81,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":399600000,"pbRate":3.55,"roa":"--","roe":"--","epsLYR":-2.64,"committee":-0.592972,"marketValue":8535000000,"floatMarketCap":4361000000,"peRate":-8.384362,"changeRate":-0.0295,"turnoverRate":0.0117,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-08-26。","afterMarket":{"amount":0,"volume":0,"close":21.36,"buyVolume":0,"sellVolume":0,"time":1724398437153,"indexStatus":"已收盘 08-23 15:30:00","preClose":22.01}},"requestUrl":"/m/hq/s/688062/tweets","defaultTab":"tweets","newsList":[{"id":"2461576345","title":"迈威生物(688062)8月23日主力资金净卖出551.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461576345","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461576345?lang=zh_cn&edition=full","pubTime":"2024-08-24 08:21","pubTimestamp":1724458892,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月23日收盘,迈威生物报收于21.36元,下跌2.95%,换手率1.17%,成交量2.39万手,成交额5110.1万元。近5日资金流向一览见下表:迈威生物融资融券信息显示,融资方面,当日融资买入155.2万元,融资偿还129.51万元,融资净买入25.69万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082400007624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2461731798","title":"迈威生物最新公告:9MW2821治疗宫颈癌的Ⅲ期临床研究获得CDE同意","url":"https://stock-news.laohu8.com/highlight/detail?id=2461731798","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461731798?lang=zh_cn&edition=full","pubTime":"2024-08-22 21:20","pubTimestamp":1724332824,"startTime":"0","endTime":"0","summary":"迈威生物公告,9MW2821是公司自主研发的创新药,公司已经向国家药品监督管理局药品审评中心(简称“CDE”)递交了关于“9MW2821对比研究者选择的化疗治疗含铂化疗失败的复发或转移性宫颈癌的随机、开放、对照、多中心Ⅲ期临床研究”的方案并获得同意。公司即将启动9MW2821治疗含铂化疗失败的复发或转移性宫颈癌的Ⅲ期临床研究。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082200041325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2461964643","title":"迈威生物(688062.SH):9MW2821治疗宫颈癌的Ⅲ期临床研究获得CDE同意","url":"https://stock-news.laohu8.com/highlight/detail?id=2461964643","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461964643?lang=zh_cn&edition=full","pubTime":"2024-08-22 17:57","pubTimestamp":1724320665,"startTime":"0","endTime":"0","summary":"迈威生物(688062.SH)公告,9MW2821是公司自主研发的创新药,公司已经...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/astock/9.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/9.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168547.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK4017","688062","CDE"],"gpt_icon":0},{"id":"2461398185","title":"【迈威生物:9MW2821治疗宫颈癌III期临床研究获CDE同意】金十数据8月22日讯,迈威生物公告,公司自主研发的创新药9MW2821获得国家药品监督管理局药品审评中心同意,针对含铂化疗失败的复发或转移性宫颈癌进行III期临床研究。","url":"https://stock-news.laohu8.com/highlight/detail?id=2461398185","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461398185?lang=zh_cn&edition=full","pubTime":"2024-08-22 17:21","pubTimestamp":1724318470,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["III","BK4017","06978","159992","BK1574","BK4134","CDE","688062","BK0239","BK1161"],"gpt_icon":0},{"id":"2461066862","title":"迈威生物急需一位\"天使\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2461066862","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461066862?lang=zh_cn&edition=full","pubTime":"2024-08-21 11:09","pubTimestamp":1724209780,"startTime":"0","endTime":"0","summary":"迈威生物 就是这样一家有想法的公司。与生物类似药极为有限的预期相比,ADC则是当下最为热门的技术路线,伴随迈威生物ADC进展的持续披露,公司股价也在2023年发生天翻地覆的变化。迈威生物的预期几乎全部集中在ADC管线之上。目前,迈威生物缺少的不是预期的高度,而是来自于行业的权威认证。这三款管线的进展将对迈威生物股价走势起到决定性作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082111201695ace371&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082111201695ace371&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2460462030","title":"迈威生物-U大跌5.04% 创6月新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2460462030","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460462030?lang=zh_cn&edition=full","pubTime":"2024-08-20 13:07","pubTimestamp":1724130450,"startTime":"0","endTime":"0","summary":"08月20日,迈威生物-U股价大幅下跌,截至13点07分,迈威生物-U下跌5.04%,报22.06元/股,创近6月新低,成交3614万元,换手率0.78%。资金动向截止发稿,迈威生物-U获得主力净流出238万元,其中超大单流出212万元,大单流出24万元。北向资金方面,迈威生物-U08月16日获得北向资金增持5.86万股,截至08月16日,北向资金当前共持有迈威生物-U909.02万股,市值2.01亿元,持股占流通股比为4.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820130745a1d51faf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820130745a1d51faf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2460709244","title":"迈威生物-U08月19日主力资金流出21万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2460709244","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460709244?lang=zh_cn&edition=full","pubTime":"2024-08-19 15:19","pubTimestamp":1724051959,"startTime":"0","endTime":"0","summary":"08月19日, 迈威生物-U股价跌0.30%,报收23.23元,成交金额4925万元,换手率1.04%,振幅3.22%,量比1.11。迈威生物-U今日主力资金净流出21万元,连续3日净流出,上一交易日主力净流出381万元,今日环比减少94.49%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为70.00%,平均跌幅为1.01%。该股近5个交易日下跌4.29%,主力资金累计净流出811万元;近20日主力资金累计净流出4310万元,其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081915362795a5fead&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081915362795a5fead&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2460609817","title":"迈威生物新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2460609817","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460609817?lang=zh_cn&edition=full","pubTime":"2024-08-18 13:30","pubTimestamp":1723959044,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日迈威(上海)生物科技股份有限公司新提交1件商标注册申请。商标申请详情如下:今年以来迈威(上海)生物科技股份有限公司新申请注册商标5件,截止目前公司共持有注册商标630件,另有101件商标尚在注册申请中。数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081800001291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2458066951","title":"迈威生物最新公告:9MW2821用于尿路上皮癌适应症纳入突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2458066951","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458066951?lang=zh_cn&edition=full","pubTime":"2024-08-11 15:50","pubTimestamp":1723362620,"startTime":"0","endTime":"0","summary":"迈威生物公告,近日创新药9MW2821被国家药品监督管理局药品审评中心纳入突破性治疗品种名单,用于治疗既往铂类化疗和PD-(L)1抑制剂治疗失败的局部晚期或转移性尿路上皮癌,并已完成公示。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081100001346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2458966615","title":"迈威生物(688062.SH):9MW2821用于尿路上皮癌适应症纳入突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2458966615","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458966615?lang=zh_cn&edition=full","pubTime":"2024-08-11 15:36","pubTimestamp":1723361779,"startTime":"0","endTime":"0","summary":"智通财经APP讯,迈威生物(688062.SH)公告,公司采用自主知识产权研发的创新药9MW2821目前针对尿路上皮癌、宫颈癌、食管癌、乳腺癌等多个适应症正在开展多项临床研究。近日,9MW2821被国家药品监督管理局药品审评中心(简称“药审中心”)纳入突破性治疗品种名单,用于治疗既往铂类化疗和PD-(L)1抑制剂治疗失败的局部晚期或转移性尿路上皮癌,并已完成公示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1162638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2457189389","title":"迈威生物-U08月07日主力资金流入10万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2457189389","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457189389?lang=zh_cn&edition=full","pubTime":"2024-08-07 15:18","pubTimestamp":1723015122,"startTime":"0","endTime":"0","summary":"08月07日, 迈威生物-U股价跌1.00%,报收24.71元,成交金额4645万元,换手率0.92%,振幅3.29%,量比0.56。迈威生物-U今日主力资金净流入10万元,连续5日净流入,上一交易日主力净流入693万元,今日环比减少98.56%。该股近5个交易日下跌0.96%,主力资金累计净流入1639万元;近20日主力资金累计净流出1915万元,其中净流出天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807152737958517b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807152737958517b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2457712209","title":"迈威生物-U08月05日主力资金流入185万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2457712209","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457712209?lang=zh_cn&edition=full","pubTime":"2024-08-05 15:19","pubTimestamp":1722842375,"startTime":"0","endTime":"0","summary":"08月05日, 迈威生物-U股价跌0.04%,报收23.97元,成交金额7084万元,换手率1.42%,振幅6.26%,量比0.85。迈威生物-U今日主力资金净流入185万元,连续3日净流入,上一交易日主力净流入667万元,今日环比减少72.26%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为50.00%,平均涨幅为2.99%。该股近5个交易日上涨1.52%,主力资金累计净流出122万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流出3931万元,其中净流出天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805154238957e4ea5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805154238957e4ea5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2457762404","title":"迈威生物-U大幅上涨 上海生物医药产业快速发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2457762404","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457762404?lang=zh_cn&edition=full","pubTime":"2024-08-05 09:48","pubTimestamp":1722822494,"startTime":"0","endTime":"0","summary":"08月05日,迈威生物-U股价大幅上涨,截至09点48分,迈威生物-U上涨5.05%,报25.19元/股,成交1424万元,换手率0.28%,振幅5.88%。这些转变推动了上海生物医药产业发展进入快车道,去年产业规模超9000亿元。北向资金方面,迈威生物-U08月02日获得北向资金增持0.29万股,截至08月02日,北向资金当前共持有迈威生物-U853.79万股,市值2.15亿元,持股占流通股比为4.18%。主营业务及业绩迈威生物-U公司主营业务为治疗用生物制品的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805094934af95d40d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805094934af95d40d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["399441","BK0239","161726","688062"],"gpt_icon":0},{"id":"2456410366","title":"迈威生物-U大幅上涨 创新药政策利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2456410366","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456410366?lang=zh_cn&edition=full","pubTime":"2024-08-02 09:53","pubTimestamp":1722563638,"startTime":"0","endTime":"0","summary":"08月02日,迈威生物-U股价大幅上涨,截至09点53分,迈威生物-U上涨5.01%,报25.16元/股,成交2791万元,换手率0.56%。消息解读2024年,国家药品监督管理局批复同意在北京、上海开展优化创新药临床试验审评审批试点,要求北京市药品监督管理局和上海市药品监督管理局严格按照《优化创新药临床试验审评审批试点工作方案》要求组织开展试点工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802095440aefcd454&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802095440aefcd454&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","159992","BK0239"],"gpt_icon":0},{"id":"2456048681","title":"【迈威生物(688062.SH)子公司与润佳医药签订许可协议 为骨关节炎治疗领域注入新产品】智通财经APP讯,迈威生物(688062.","url":"https://stock-news.laohu8.com/highlight/detail?id=2456048681","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456048681?lang=zh_cn&edition=full","pubTime":"2024-08-01 18:32","pubTimestamp":1722508343,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["688062","09939","BK1515","BK1161","159938","BK1574","399441","BK0239","161726"],"gpt_icon":0},{"id":"2456027101","title":"迈威生物(688062.SH)子公司与润佳医药签订许可协议 为骨关节炎治疗领域注入新产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2456027101","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456027101?lang=zh_cn&edition=full","pubTime":"2024-08-01 18:32","pubTimestamp":1722508343,"startTime":"0","endTime":"0","summary":"智通财经APP讯,迈威生物 公告,公司全资子公司江苏泰康生物医药有限公司与润佳(苏州)医药科技有限公司就在研品种RP901项目签署《许可协议》。根据许可协议,润佳医药许可泰康生物在大中华区域内研究、开发、注册、商业化以及销售RP901项目及伴随诊断的权益。据悉,公司在骨科领域已有药物布局,本次许可产品RP901拟开发成用于骨关节炎口服治疗的1类新药。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1158869.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","09939","BK0239","688062","159938","BK1574","BK1515"],"gpt_icon":0},{"id":"2456058281","title":"迈威生物(688062.SH):全资子公司与润佳医药签订许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2456058281","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456058281?lang=zh_cn&edition=full","pubTime":"2024-08-01 17:40","pubTimestamp":1722505212,"startTime":"0","endTime":"0","summary":"格隆汇8月1日丨迈威生物(688062.SH)公布,公司全资子公司泰康生物与润佳医药经友好协商,就润佳医药在研品种RP901项目签署许可协议,润佳医药许可泰康生物在大中华区域(包括中国大陆、香港、澳门和台湾)内研究、开发(包括通过合同研究组织研究或开发)、注册、商业化以及销售RP901项目及伴随诊断(仅为使用许可产品之目的开发)的权益。根据协议,润佳医药将收到首付款5,000万元人民币,最高可达10.7亿元人民币的研发及注册里程碑、商业里程碑款,以及至高净销售额10%的提成费。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408011740419f05241e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408011740419f05241e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","159938","BK0239"],"gpt_icon":0},{"id":"2456210355","title":"迈威生物:全资子公司与润佳医药签订许可协议迈威生物公告,全资子公司泰康生物与润佳医药签订许可协议,润佳医药许可泰康生物在大中华区域研究、开发、注册、商业化及销售RP901项目及伴随诊断。","url":"https://stock-news.laohu8.com/highlight/detail?id=2456210355","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456210355?lang=zh_cn&edition=full","pubTime":"2024-08-01 17:35","pubTimestamp":1722504931,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["09939","BK1574","BK0239","159938","688062","BK1161","BK1515"],"gpt_icon":0},{"id":"2456366128","title":"迈威生物-U大跌5.01% 北向资金连续6日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2456366128","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456366128?lang=zh_cn&edition=full","pubTime":"2024-08-01 11:29","pubTimestamp":1722482981,"startTime":"0","endTime":"0","summary":"08月01日,迈威生物-U股价大幅下跌,截至11点29分,迈威生物-U下跌5.01%,报23.70元/股,成交4495万元,换手率0.90%。北向资金方面,迈威生物-U07月31日获得北向资金增持41.38万股,连续6日增持,截至07月31日,北向资金当前共持有迈威生物-U852.21万股,市值2.02亿元,持股占流通股比为4.17%。主营业务及业绩迈威生物-U公司主营业务为治疗用生物制品的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240801113006af9545a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240801113006af9545a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2455894118","title":"迈威生物-U大幅上涨 生物医药产业获政策利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2455894118","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455894118?lang=zh_cn&edition=full","pubTime":"2024-07-31 10:12","pubTimestamp":1722391928,"startTime":"0","endTime":"0","summary":"此次《意见》中,推出了若干支持举措,为上海生物医药产业国际化发展提供支撑和保障。近日,上海市出台了《关于支持生物医药产业全链条创新发展的若干意见》,其中提出,推动行业数据安全合规流动。上海市副市长刘多表示,生物医药是上海市重点发展的三大先导产业之一。主营业务及业绩迈威生物-U公司主营业务为治疗用生物制品的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240731101309af94f8c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240731101309af94f8c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["399441","BK0239","161726","688062"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-01-18","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路230号2幢105室","stockEarnings":[{"period":"1week","weight":-0.0833},{"period":"1month","weight":-0.148},{"period":"3month","weight":-0.3418},{"period":"6month","weight":-0.242},{"period":"1year","weight":-0.0157},{"period":"ytd","weight":-0.3466}],"companyName":"迈威(上海)生物科技股份有限公司","boardCode":"AI0027","perCapita":"13667股","boardName":"医药制造业","registeredCapital":"39960万元","compareEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0164},{"period":"3month","weight":-0.0759},{"period":"6month","weight":-0.0501},{"period":"1year","weight":-0.0739},{"period":"ytd","weight":-0.0405}],"survey":" 迈威(上海)生物科技股份有限公司是一家创新型生物制药企业,主营业务为治疗用生物制品的研发、生产与销售,主要产品为抗体药物。截至本招股说明书签署日,新增授权专利4项,新增专利申请48项,独立承担1项国家“重大新药创制”重大科技专项,独立承担2项国家重点研发计划。","serverTime":1724530397696,"listedPrice":34.8,"stockholders":"14938人(较上一季度减少16.14%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物,688062,迈威生物股票,迈威生物股票老虎,迈威生物股票老虎国际,迈威生物行情,迈威生物股票行情,迈威生物股价,迈威生物股市,迈威生物股票价格,迈威生物股票交易,迈威生物股票购买,迈威生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}